PARP14 Inhibitor Program

PARP14 Inhibitor Program — Targeting Stress Support Pathways Driven by M2 Immunosuppressive Macrophages

We are developing small molecule inhibitors of PARP14, an attractive and highly promising oncology target. We believe inhibition of PARP14 can cause tumor macrophages to stimulate the immune system to kill cancer. PARP14 is overexpressed in many solid tumors, including breast and kidney cancers, and has been linked to immunosuppression through its effects on macrophages. We believe that inhibiting PARP14 has the potential to shift the differentiation of macrophages from a pro-tumorigenic M2 phenotype to an anti-tumorigenic M1 phenotype and thereby activate a robust antitumor immune response. We are not aware of any approved drugs or drug development programs that target PARP14.